RYTM News and Press, Rhythm Pharmaceuticals Inc. From 01/26/21

Rhythm Pharmaceuticals (RYTM) announces positive data from multiple cohorts in its Phase 2 Basket Study evaluating setmelanotide for the treatment of severe obesity due to genetic variants in the melanocortin-4 receptor (MC4R) pathway.Clinical data from five cohorts totaling 65 patients demon...

-- Clinical data from Phase 2 Basket Study including five cohorts totaling 65 patients demonstrated proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, SRC1 and SH2B1 deficiency obesities – -- Phase 2 Basket Study responder rates and updated sequencing results sugge...

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) is expected in the second half of 2021. The company is in great financial shape ...

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it plans to host a virtual event on Tuesday, Januar...

Rhythm Pharmaceuticals (RYTM) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $100M. The PRV was granted to Rhythm by the U.S. FDA with the approval of IMCIVREE™, proprotein convertase subtilisin/kexin type 1 or leptin receptor def...

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell ...

Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director PR Newswire ZUG, Switzerland , Jan. 5, 2021 /PRNewswire/ -- Pharvaris , a clinical-stage company focused on the discovery and developm...

Rhythm Pharmaceutical (RYTM) gains 9% in premarket, on announcement of positive topline results from Phase 3 trial evaluating setmelanotide, for the treatment of insatiable hunger and severe obesity in individuals with Bardet-Biedl syndrome ((BBS)) or Alström syndromeThe study ...

-- Study met primary endpoint and all key secondary endpoints with statistically significant and clinically meaningful reductions in weight and hunger -- -- All primary endpoint responders were patients with BBS -- -- Plan to submit sNDA to FDA for BBS in the second half...

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn...